Telix reports 53% revenue growth, raises guidance

🌟 Big news for Epion Therapeutics! 🌟 We’re excited to share that the 𝗨.𝗦. 𝗙𝗼𝗼𝗱 𝗮𝗻𝗱 𝗗𝗿𝘂𝗴 𝗔𝗱𝗺𝗶𝗻𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 (𝗙𝗗𝗔) 𝗵𝗮𝘀 𝗴𝗿𝗮𝗻𝘁𝗲𝗱 𝗙𝗮𝘀𝘁 𝗧𝗿𝗮𝗰𝗸 𝗱𝗲𝘀𝗶𝗴𝗻𝗮𝘁𝗶𝗼𝗻 for 𝗘𝗽𝗶𝗦𝗺𝗮𝗿𝘁 𝗘𝗽𝗶𝘁𝗵𝗲𝗹𝗶𝘂𝗺-𝗢𝗻 𝗖𝗿𝗼𝘀𝘀-𝗟𝗶𝗻𝗸𝗶𝗻𝗴 𝗦𝘆𝘀𝘁𝗲𝗺, our novel drug-device combination designed to treat keratoconus. Fast Track designation is intended to expedite development and review of drugs that 𝘁𝗿𝗲𝗮𝘁 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝗰𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝘀 and 𝗳𝗶𝗹𝗹 𝗮𝗻 𝘂𝗻𝗺𝗲𝘁 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗻𝗲𝗲𝗱. This designation marks an important step forward in our effort to bring a safe, accessible, and minimally-invasive treatment to millions of keratoconus patients worldwide. 🔗 Read the full announcement: https://lnkd.in/e-aNquj5 #Keratoconus #Ophthalmology #CrossLinking #CornealCrossLinking #FDA #FastTrack

Series B rounds abound with Kardigan raising $254M and Kailera Therapeutics pulling in $600M. Kardigan is advancing three cardiovascular assets into late-stage clinical trials, while Kailera is focused on its obesity pipeline and global phase III efforts. The financings represent the top two series B rounds of biopharma companies in 2025.   Read Karen Carey’s report in BioWorld News: https://lnkd.in/ecnnpWCm (Access this exclusive content with a Premium BioWorld subscription: https://lnkd.in/ex_sZAtE) #biopharma #cardiovascular #obesity Clarivate for Life Sciences & Healthcare

Patient-centric clinical trials place the lived experience of patients at the center of drug development, ensuring that therapies not only demonstrate efficacy but also meaningfully fit into patients’ daily lives. For its part, Unicycive Therapeutics directly solicits patient input through structured questionnaires, trial site partnerships, and open communication to help guide its intention to reduce treatment burden and improve quality of life. In this Q&A, Unicycive CEO Shalabh Gupta, MD, shares how the company integrates patient feedback into the design of its trials, from addressing the overwhelming pill burden of dialysis patients to building trust through long-standing care relationships. Read the Q&A 📎 https://lnkd.in/eFgcJdQB #clinicaltrials #clinicalresearch

How do we get groundbreaking medicines to patients faster? Strand Therapeutics CEO Jacob Becraft unpacks what it really takes, why medicine is the best investment, and how policy needs to reflect that. 🎙️ Watch his conversation with Benchling CEO Sajith Wickramasekara: https://lnkd.in/eVVDn79z #Transcribed

https://lnkd.in/ezFBm5ct CLINICAL TRIALS - Keeping Pace With Shifting Drug Development Paradigms for Multi-Indication Therapies: Simon Bruce, MD, and Jack L. Martin, MD, indicate that as developers increasingly embrace multi-indication development, the success of multi-indication therapies will stem not merely from pipeline adjustments, but also from development strategies designed with multi-indication objectives at their core.

Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination https://lnkd.in/dT5Qzs6R RELIEF THERAPEUTICS Holding SA NeuroX Gregory Van Beek Tej Tadi Jeremy Meinen >Transaction to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company > Combined company to be renamed MindMaze Therapeutics Holding SA upon closing > More DACH Region Life Science Business News at [LSG] Life-Sciences-Germany.com __

𝗙𝗿𝗮𝗰𝘁𝘆𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 $𝟲𝟬𝗠 𝘂𝗻𝗱𝗲𝗿𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝗼𝗳𝗳𝗲𝗿𝗶𝗻𝗴 𝗼𝗳 𝗰𝗼𝗺𝗺𝗼𝗻 𝘀𝘁𝗼𝗰𝗸 💰 #Metabolic therapeutics company Fractyl Health has priced an offering of 60 million shares at $1.00 per share, raising gross proceeds of ~$60 million. All shares are being offered by the company, with the deal expected to close on or around September 29, 2025, subject to standard closing conditions. Bank of America Securities and Evercore ISI are acting as joint book-running managers, while Ladenburg Thalmann serves as lead manager. Fractyl Health is pioneering organ-targeted, disease-modifying therapies for #obesity and #T2D, aiming to move beyond chronic symptom management, and this new capital should support its efforts as it advances its pipeline. With 33+ granted U.S. patents and a unique therapeutic strategy, Fractyl Health is one to watch in the evolving #metabolicdisease landscape. ------------------------------------------------------------- Stay up to date with everything obesity through my newsletter 😊 https://lnkd.in/dncNKh3R

Whiteley has opened a $25 million therapeutics plant in Tomago, and Premier Chris Minns hails the facility as a milestone for jobs, innovation and healthcare manufacturing in NSW. Read what makes this such a significant step for sovereign manufacturing and healthcare innovation in Australia. https://lnkd.in/gdrjWFMq #cleaning #manufacturing #NSW

𝐁𝐚𝐲𝐞𝐬𝐢𝐚𝐧 𝐎𝐩𝐭𝐢𝐦𝐚𝐥 𝐈𝐧𝐭𝐞𝐫𝐯𝐚𝐥 (𝐁𝐎𝐈𝐍) design is an advanced, model-assisted approach used in early-phase (Phase I) clinical trials to identify the Maximum Tolerated Dose (MTD) of a new drug. The BOIN design is now recognized by the FDA as fit-for-purpose and is increasingly used in oncology and other therapeutic areas to ensure patient safety while accelerating drug development. The below slides contains detailed explannation about the BOIN design and its implementation. Kindly have a look at it and share your feedbacks. #BOINDesign #BayesianStatistics #ClinicalTrials #Biostatistics